



lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells

Huang, Peide; Li, Fengyu; Li, Lin; You, Yuling; Luo, Shizhi; Dong, Zhensheng; Gao, Qiang; Wu, Song; Br  nner, Nils; Stenvang, Jan

Published in:
Scientific Reports

DOI:
[10.1038/s41598-018-36231-4](https://doi.org/10.1038/s41598-018-36231-4)

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY](#)

Citation for published version (APA):
Huang, P., Li, F., Li, L., You, Y., Luo, S., Dong, Z., Gao, Q., Wu, S., Br  nner, N., & Stenvang, J. (2018). lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells. *Scientific Reports*, 8(1), [17970]. <https://doi.org/10.1038/s41598-018-36231-4>

SCIENTIFIC REPORTS

OPEN

lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells

Peide Huang^{1,3,4}, Fengyu Li³, Lin Li³, Yuling You³, Shizhi Luo³, Zhensheng Dong³, Qiang Gao³, Song Wu², Nils Br  nner¹ & Jan Stenvang¹

Resistance to adjuvant systemic treatment, including taxanes (docetaxel and paclitaxel) is a major clinical problem for breast cancer patients. lncRNAs (long non-coding RNAs) are non-coding transcripts, which have recently emerged as important players in a variety of biological processes, including cancer development and chemotherapy resistance. However, the contribution of lncRNAs to docetaxel resistance in breast cancer and the relationship between lncRNAs and taxane-resistance genes are still unclear. Here, we performed comprehensive RNA sequencing and analyses on two docetaxel-resistant breast cancer cell lines (MCF7-RES and MDA-RES) and their docetaxel-sensitive parental cell lines. We identified protein coding genes and pathways that may contribute to docetaxel resistance. More importantly, we identified lncRNAs that were consistently up-regulated or down-regulated in both the MCF7-RES and MDA-RES cells. The co-expression network and location analyses pinpointed four overexpressed lncRNAs located within or near the *ABCB1* (ATP-binding cassette subfamily B member 1) locus, which might up-regulate the expression of *ABCB1*. We also identified the lncRNA EPB41L4A-AS2 (EPB41L4A Antisense RNA 2) as a potential biomarker for docetaxel sensitivity. These findings have improved our understanding of the mechanisms underlying docetaxel resistance in breast cancer and have provided potential biomarkers to predict the response to docetaxel in breast cancer patients.

Breast cancer is the most frequently diagnosed cancer among females and the leading cause of cancer death among women worldwide¹. Multiple treatment modalities are used in breast cancer, such as surgery, radiation therapy, chemotherapy and target therapy. Taxanes, including docetaxel and paclitaxel, are among the most commonly used chemotherapeutic agents to treat breast cancer². However, patients receiving a taxane treatment may become resistant to taxanes, thus resulting in recurrence and metastatic disease.

To reduce patient suffering from disease recurrence caused by taxane resistance, researchers focus on the molecular mechanisms and predictive biomarkers of taxane resistance at multiple levels. Several genes are associated with taxane resistance. The differential expression of the *ABCB1* gene is one of the most studied putative biomarkers in taxane-resistant cancers^{3,4}. Pgp (permeability glycoprotein), encoded by the *ABCB1* gene, has been reported to act as an ATP-dependent efflux pump and reduce taxane concentration by expelling the drug⁵. Other genes, such as *ABCG2* (ATP binding cassette subfamily G member 2)⁶ *ABCB4* (ATP binding cassette subfamily B member 4)⁷ are also involved in the process of taxane resistance. However, the underlying mechanism of taxane resistance in breast cancer is still not fully elucidated, and the regulators of the taxane-resistant genes remain unknown. As a result, there are presently no predictive biomarkers for taxanes in clinical use.

Long non-coding RNAs (lncRNAs) are defined as RNAs longer than 200 nucleotides, with little potential in protein coding. Many lncRNAs are described to influence mRNA generation and expression⁸. Recent studies have shown that lncRNAs are also implicated in chemotherapy resistance. The lncRNA HOTAIR (HOX

¹Section of Pharmacotherapy, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen N, Denmark. ²The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital Group, Shenzhen, China. ³BGI Genomics, BGI-Shenzhen, Shenzhen, 518083, China. ⁴The First Affiliated Hospital of Shenzhen University, Shenzhen, China. Peide Huang, Fengyu Li and Lin Li contributed equally. Correspondence and requests for materials should be addressed to S.W. (email: doctor_wusong@126.com) or N.B. (email: nbr@sund.ku.dk) or J.S. (email: stenvang@sund.ku.dk)

Sample	MCF7_12_P	MCF7_14_P	MCF7_15_P	MCF7_13_T	MCF7_14_T	MCF7_15_T	MDA_13_P	MDA_14_P	MDA_16_P	MDA_14_T	MDA_15_T	MDA_16_T
Number of raw reads	155,368,324	150,086,362	154,603,830	151,890,702	146,565,380	150,531,888	154,601,446	150,960,982	155,560,554	150,067,038	154,602,638	151,145,840
Raw data size (Gb)	13.98	13.51	13.91	13.67	13.19	13.55	13.91	13.59	14.00	13.51	13.91	13.60
Number of clean reads	147,254,586	145,503,292	148,444,124	145,691,082	141,393,020	143,013,044	149,175,500	146,265,718	146,883,552	144,846,612	149,085,610	142,568,132
Clean data size (Gb)	13.25	13.10	13.36	13.11	12.73	12.87	13.43	13.16	13.22	13.04	13.42	12.83
Clean data/Raw data (%)	94.78	96.95	96.02	95.92	96.47	95.01	96.49	96.89	94.42	96.52	96.43	94.32
Q30 reads (%)	88.66	92.75	89.63	89.73	92.72	88.81	90.36	92.57	89.23	92.96	90.54	88.38
GC (%)	49.87	47.26	49.83	49.46	47.33	49.89	47.54	46.84	47.42	46.58	48.24	49.61
Reads mapped to genome	126,241,357	129,177,823	134,000,511	133,059,665	125,613,559	122,233,249	133,556,825	129,562,173	126,202,348	128,884,515	132,119,668	118,246,009
Mapping rate (%)	85.73	88.78	90.27	91.33	88.84	85.47	89.53	88.58	85.92	88.98	88.62	82.94

Table 1. Summary of data yield and quality control. For the sample names, P represents the parental cells, T represents the docetaxel-resistant cells, number represents the passage.

Transcript Antisense RNA is reported to contribute to cisplatin resistance in human lung adenocarcinoma cells via down-regulating p21^{WAF1/CIP1} expression⁹. Another study found that the lncRNA MRUL (multidrug resistance related and up-regulated lncRNA) promotes *ABCB1* expression in multidrug-resistant gastric cancer¹⁰. More recently, data have shown that two lncRNAs, ROR (regulator of reprogramming) and CCAT1 (colon cancer-associated transcript-1), regulate docetaxel resistance in lung adenocarcinoma^{11,12}. Furthermore, from a transcriptome microarray study, the lncRNAs HIF1A-AS2 (HIF1A Antisense RNA 2) and AK124454 were shown to promote cell proliferation and invasion in TNBC (triple-negative breast cancers) cells and contribute to paclitaxel resistance¹³. However, the contribution of lncRNAs to docetaxel resistance in breast cancer is still unclear.

In this study, we carried out whole transcriptome sequencing in two cell lines, MCF-7 and MDA-MB-231, and in their docetaxel-resistant sublines, MCF7-RES and MDA-RES. We identified significantly differentially expressed (SDE) mRNAs and lncRNAs between the parental and resistant sublines, and we also uncovered the potential relationship between the SDE mRNAs and lncRNAs. Compared with previous studies, we discovered several novel genes in addition to *ABCB1* which might contribute to the taxane-resistant phenotype of breast cancers. More important, we identified a group of lncRNAs that might potentially regulate taxane sensitivity by controlling the expression of chemotherapy-resistant genes.

Results

Sequencing results and quality control. By performing Illumina-based RNA-Seq sequencing, a total of 1,825,984,984 raw reads were produced from the 12 RNA samples (3 independent samples from each cell line (Table 1)). After quality control, 1,750,124,272 clean reads (157.5 Gb) were obtained.

The proportion of clean reads among the raw reads of the 12 samples ranged from 94.32% to 96.95%. The proportion of clean reads with a Phred quality value greater than 30 among the samples ranged from 88.38% to 92.96%. The GC (guanine and cytosine nucleotides) content of the clean reads of the 12 samples ranged from 47.26% to 49.89%. In total, 82.94% to 91.33% of the clean reads were aligned against the human reference genome (Table 1).

Overview of mRNA expression and the significantly differentially expressed mRNAs between the parental and docetaxel-resistant cell groups. A total of 13,714 mRNAs were detected. More than 97.81% of the mRNAs was detected simultaneously among 3 passages of the same cell line (Sup Fig. 1A). The FPKM (fragments per kilobase million) values of the 13,714 mRNAs from 12 samples were centralized and normalized for the PCA (Principal component analysis). The results show that PC1 (Principal component 1) accounted for 52.28% of the total variance and could separate the MDA cells from the MCF7 cells; PC2 (Principal component 2) accounted for 13.91% of the total variance and separated the parental and docetaxel-resistant MDA cells. However, parental and docetaxel-resistant MCF7 cells clustered together (Sup Fig. 1B).

Differentially expressed mRNAs between the parental and docetaxel-resistant cell groups were calculated by DESeq in the two cell lines. The criteria of $|\log_2FC| > 1$ (\log_2 (fold change)), $FDR < 0.1$ (false discovery rate) was used to select the SDE mRNAs. We identified 1630 and 957 SDE mRNAs in the MDA-RES and MCF7-RES groups by comparing them to their parental groups, respectively, as shown in the volcano figure (Fig. 1A).

In the MDA-RES cells, 782 mRNAs were significantly up-regulated, and 848 mRNAs were significantly down-regulated. In the MCF7-RES cells, 627 mRNAs were significantly up-regulated, and 330 mRNAs were significantly down-regulated.




Figure 1. Overview of the mRNA expression and significantly differentially expressed mRNAs between the parental and docetaxel-resistant cell groups. (A) Volcano figure showing the significantly differentially expressed genes in the MDA-RES and MCF7-RES cells in comparison to their parental cells. The blue dots represent mRNAs with $|\text{Log}_2\text{FC}| > 1$, $\text{FDR} < 0.1$. (B) Venn diagrams of the significantly up-regulated or down-regulated mRNAs in both of the cells. (C) Complete-linkage clustering with the 124 consistent SDE mRNAs in the 12 samples. D. KEGG pathway enrichment and GO analysis for the consistent SDE genes. Left panel: GO functional classification of the consistent SDE genes. Red, green, and blue represent the three classes of the GO term. The top 10 enriched GO terms are shown in each class. Right panel: Scatter plot for the KEGG enrichment of the consistent SDE genes. RichFactor is the ratio of the consistent SDE genes annotated in a pathway to all the genes in this pathway. The Q value is the corrected p-value. The top 14 pathways with a Q value < 0.05 are shown in the figure.

The most studied MDR (multidrug resistance) related gene, *ABCB1* was dramatically up-regulated in both the MDA-RES and MCF7-RES cells (Fig. 1A), which was consistent with a previous report⁴. The top ten significantly up- or down-regulated genes in the MDA-RES or MCF7-RES cells are shown in Sup Table 1.

By analyzing the list of significantly up-regulated and down-regulated mRNAs in the MDA-RES and MCF7-RES cells, we found 80 mRNAs that were consistently up-regulated and 44 mRNAs that were consistently down-regulated in both of the cells (Fig. 1B, Sup Table 2).

Using these 124 consistent SDE mRNAs, the 12 samples were clustered into two groups (MDA-MB-231 and MCF-7) (Fig. 1C), which indicated that the mRNA diversity between the MCF-7 cells and MDA-MB-231 cells was greater than that between the docetaxel-resistant and parental cells.

GO (Gene ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses of the significantly differentially expressed genes.

A KEGG pathway analysis was performed in each cell line. In the MCF7-RES cells, the three most enriched KEGG pathways associated with the SDE mRNAs were the metabolic pathways, axon guidance, and neuroactive ligand-receptor interaction. However, other pathways, such as the PI3K-Akt signaling pathway, Wnt signaling pathway, ECM-receptor interaction and ABC transporters, were also significantly enriched (Sup Fig. 2).

In the MDA-RES cells, the PI3K-Akt signaling pathway, cytokine-cytokine receptor interaction, and pathways in cancer were the top three pathways, followed by the metabolic pathway, AGE-RAGE signaling pathway, and the cell adhesion molecules (CAMs) pathway. Furthermore, ABC transporters, the MAPK signaling pathway and ECM-receptor interaction were also significantly enriched (Sup Fig. 3).

We also performed the KEGG pathway analysis on the 124 consistent SDE mRNAs shared by the MCF7 and MDA cells. As shown in Fig. 1D, 14 signaling pathways were significantly enriched (Q value < 0.05). The most significantly enriched pathway was the cGMP-PKG signaling pathway. However, the ABC transporters, PI3K-Akt signaling pathway, AGE-RAGE signaling pathway in diabetic complications, and HIF-1 signaling pathway were also significantly enriched.

A GO analysis for the consistent SDE mRNAs was also performed to identify the function of the coding transcripts. With regard to biological processes, the most enriched GO term associated with the consistent SDE mRNAs was cellular process. With regard to the cellular component, the most enriched GO terms were cell and cell part. Moreover, the most enriched GO terms associated with the consistent SDE mRNAs for molecular function were binding and protein binding (Fig. 1D).

Overview of lncRNA expression and the significantly differentially expressed lncRNAs between the parental and docetaxel-resistant cell groups.

NONCODE 2016 was used to annotate the lncRNAs. The lncRNAs were classified into 4 subgroups as antisense, exonic, linc (long intergenic non-coding), and sense no exonic lncRNAs, according to their location and their relationship with nearby genes. The classification of the lncRNAs in the NONCODE database was provided online (http://www.noncode.org/datadownload/NONCODE2016_human_cc.tgz). We found that lincRNAs and antisense lncRNAs were the two most abundant subtypes in all the cell lines (Fig. 2A).

A total of 39,363 lncRNAs were identified in the 12 RNA samples. More than 81.55% of the lncRNAs were detected simultaneously among three independent passages of the same cell line (Sup Fig. 3A). The differentially expressed lncRNAs between the parental and docetaxel-resistant cell groups were calculated by DESeq. We identified 2,150 and 815 SDE lncRNAs ($|\log_2FC| > 1$, FDR < 0.1) in MDA-RES and MCF7-RES groups (Fig. 2B,C). The SDE lncRNAs identified in the MDA-RES cells included 415 antisense lncRNAs, 1179 intergenic lncRNAs, 429 exonic lncRNAs and 127 sense no exonic lncRNAs. While in the MCF7-RES cells, the SDE lncRNAs included 184 antisense lncRNAs, 435 intergenic lncRNAs, 161 exonic lncRNAs, and 35 sense no exonic lncRNAs (Fig. 2C).

By analyzing the list of SDE lncRNAs in the MCF7-RES and MDA-RES cells, we found 50 lncRNAs that were consistently up-regulated, while 22 lncRNAs were consistently down-regulated in both the MCF7-RES and MDA-RES cell lines (Fig. 2C, Sup Table 3).

By performing complete-linkage clustering with these consistent SDE lncRNAs, the 12 samples were clustered into two groups (parental and resistant) perfectly (Fig. 2D).

lncRNA-mRNA co-expression network construction and docetaxel-resistant module detection.

It is well documented that lncRNAs function as regulators of target mRNAs^{8,14}. Additionally, lncRNAs and their target mRNAs usually present similar expression patterns¹⁵⁻¹⁷. To predict the target mRNAs of the lncRNAs, we used the WGCNA (weighted gene co-expression network analysis)¹⁸ R software package to detect similar expression patterns between the SDE lncRNAs and mRNAs.

All the SDE genes (72 lncRNAs and 124 mRNAs) were subjected to the WGCNA analysis. We identified 4 groups of co-expressed genes, termed 'modules' (Fig. 3A). Each module was labeled with a unique color underneath the cluster tree¹⁹.

Inside a given module, the expression profiles of the transcripts can be summarized by the 'module eigengene', which is the weighted average of the module gene expression profiles¹⁹. To identify the module associate with docetaxel-resistant status, we regressed each of the 4 module eigengenes on docetaxel-resistant status. We found that the Turquoise and Gray modules were most significantly associated with docetaxel-resistant status (Fig. 3B). Of these 2 associated modules, the Turquoise was positively correlated with docetaxel resistance, meaning that the genes in this module are predominantly up-regulated in docetaxel-resistant cells. In contrast, the Gray module was negatively correlated with a docetaxel-resistant status, meaning that most genes in this module were down-regulated in the docetaxel-resistant cells.




Figure 2. Overview of the lncRNA expression and significantly differentially expressed lncRNAs between the parental and docetaxel-resistant cell groups. (A) The subgroups and number of lncRNAs detected in the docetaxel-resistant and parental cell lines (P represents the parental cell line; T represents the docetaxel-resistant cell line). (B) Volcano figure showing the significantly differentially expressed lncRNAs in the MDA-RES and MCF7-RES cells compared to their parental cells. The blue dots represent lncRNAs with $|\log_2FC| > 1$, $FDR < 0.1$. (C) Upper panel: Venn diagrams of consistently up-regulated or down-regulated lncRNAs in both of the MDA-RES and MCF7-RES cells. Lower panel: the bar chart shows the subgroups and numbers of significantly up-regulated or down-regulated lncRNAs. (D) Complete-linkage clustering with the 72 consistent SDE lncRNAs in the 12 samples.

To identify the genes that are central and highly connected in the docetaxel-resistance-associated modules, we selected Hub genes with $|GS| > 0.4$ (gene significance) and $|MM| > 0.8$ (module membership) in the two modules and visualized these genes by Cytoscape (Fig. 3C).

In the Turquoise module, we identified 59 hub genes, including 40 protein coding genes and 19 lncRNAs (Sup Table 4). Several well-known chemotherapy-resistance-associated genes including *ABCB1* were found in the protein coding genes list. We found that 39 genes, including 22 protein coding and 17 non-coding, were




Figure 3. lncRNA-mRNA co-expression network construction and docetaxel-resistant module detection using the consistent SDE mRNAs and lncRNAs. **(A)** A total of 72 SDE lncRNAs and 124 SDE mRNAs were subjected to the WGCNA analysis. Using the hierarchical clustering method, 4 groups of co-expressed genes, termed ‘modules’, were identified. **(B)** The 4 modules were related to the docetaxel-resistant status. The correlation coefficients representing the module-trait relationships are indicated in the center of the modules, and the corresponding P-values are in the brackets. **(C)** The hub genes in the Turquoise and Gray modules were visualized by Cytoscape. Pathway enrichment was performed with the hub genes in the two modules. a. The connections of the 59 hub genes in the Turquoise module. The white nodes represent the hub genes, and the red lines indicate the connections to *ABCB1*. b. The connections of the 29 hub genes in the Gray module. The white nodes represent the hub genes, and the red lines indicate the connections to NONHSAG041250.2 (EPB41L4A-AS2).

linked to *ABCB1* (Table 2). Among the 22 coding genes linked to *ABCB1*, we found that many of the genes are implicated in drug or chemotherapy resistance, such as *ABCB4*, *ADAM22* (disintegrin and metalloproteinase domain-containing protein 22), *GNMB* (glycoprotein nmb), *COL21A1* (collagen type XXI alpha 1 chain), and *ITGB4* (integrin subunit beta 4) (Table 2, marked with asterisks). Strikingly, we found a list of lncRNAs closely

Node links to ABCB1	Region	Log ₂ (MCF-RES/MCF-7)	MCF padj	Log ₂ (MDA-RES/MDA-MB-231)	MDA padj
ABCB4*	chr7:87031361-87105019	4.391873563	3.0392E-81	4.798895486	1.78397E-10
ADAM22*	chr7:87563566-87832204	3.031204518	5.24574E-71	2.042465751	8.48915E-17
C1orf226	chr1:162348696-162356608	1.30617006	2.08367E-08	1.218567139	0.002493763
CCL5	chr17:34198495-34207377	4.281358914	2.28917E-14	3.425308925	0.016192984
CNGB3	chr8:87586024-87755903	2.927154653	8.53446E-07	4.3137896	4.17421E-05
COL21A1*	chr6:55921388-56112378	4.89902163	1.49237E-23	3.061434362	0.004363835
FAXDC2	chr5:154198052-154230213	1.236440283	7.16651E-08	2.057091728	0.002687024
GPNMB*	chr7:23286316-23314729	3.634939682	3.41382E-06	3.979523007	5.07143E-21
GUCY1A2	chr11:106557910-106889171	3.923885806	3.04573E-08	2.419615258	0.008199061
ITGB4*	chr17:73717516-73753899	1.264990464	3.44083E-05	1.28963119	1.4676E-10
MAP1A	chr15:43809806-43823818	1.820284794	0.005866863	2.930015235	4.37426E-12
NEB	chr2:152341853-152591001	5.071449042	1.95162E-15	1.272976565	0.074560694
NOS3	chr7:150688144-150711687	4.229375395	6.48733E-15	1.677234009	0.009459785
P2RX7	chr12:121570631-121624354	3.174388573	3.15828E-08	3.742594891	0.024211279
PALMD	chr1:100111431-100160097	3.418917876	1.04212E-12	3.476080265	0.000185888
PCLO	chr7:82383321-82792197	5.256273053	6.619E-18	1.320153124	0.000404159
PTHLH	chr12:28111017-28124916	5.660286658	2.89989E-37	1.102001097	0.022862275
RORC	chr1:151778547-151804348	2.438996823	2.19322E-10	2.525862773	0.011217021
RUNDC3B	chr7:87257729-87461613	3.889364599	2.65512E-25	2.527876138	1.00736E-12
SEMA3E	chr7:82993222-83278479	3.4028601	3.31146E-90	3.774037375	3.23296E-38
STK31	chr7:23749838-23872132	4.004572338	6.89337E-33	1.460119768	0.003048511
TBX20	chr7:35242042-35293711	3.537902823	0.000168179	3.453322279	0.025040493
NONHSAG002193.2	chr1:100111502-100152712	2.306183482	0.00000108	1.765770312	0.035443541
NONHSAG013923.2	chr13:89793303-89815434	2.858465834	4.82E-10	2.473788666	0.000298561
NONHSAG048134.2	chr7:87150777-87151726	4.661655972	4.16E-34	4.849823297	1.08E-20
NONHSAG048135.2	chr7:87229434-87342570	3.06347186	6.79E-13	3.485170506	3.16E-09
NONHSAG048143.2	chr7:87829109-87832202	3.266694083	3.73E-33	1.013242299	0.016081777
NONHSAG051078.2	chr8:115582746-115686229	3.00855	2.46E-23	1.929201108	0.008762611
NONHSAG067189.1	chr13:89594992-89616155	5.165615	7.06E-47	3.947107328	1.03E-13
NONHSAG067198.1	chr13:91322334-91371571	3.65213	2.43E-20	2.165973989	0.003256962
NONHSAG067199.1	chr13:91465148-91472109	4.027848	2.53E-24	2.187822303	0.000869085
NONHSAG085133.1	chr3:165592410-165780111	2.821382	1.38E-20	5.039315468	1.02E-23
NONHSAG085134.1	chr3:165609026-165630375	2.314128	1.26E-09	3.197328113	0.000000284
NONHSAG085135.1	chr3:165633442-165636497	2.229836	1.85E-09	3.518443205	9.92E-10
NONHSAG085136.1	chr3:165651727-165888351	1.995099	0.000138828	1.567863816	0.09203305
NONHSAG085734.1	chr3:126760621-126763555	1.264793	0.05765945	1.590391302	0.083859182
NONHSAG096192.1	chr7:23296654-23301401	2.382385	1.7E-09	3.160102464	2.15E-08
NONHSAG096479.1	chr7:87075330-87214789	7.059226	1.77E-99	7.209915426	7.23E-58
NONHSAG096480.1	chr7:87445537-87459755	2.385153266	9.27E-10	1.169846587	0.062398465

Table 2. Nodes links to ABCB1 in the Turquoise module. *Asterisk indicates the gene which has been implicated in chemotherapy resistant; padj refer to adjusted P value.

linked to *ABCB1* in the Turquoise module (Table 2), indicating that these lncRNAs may function as regulators of *ABCB1*.

In the Gray module, we identified 29 hub genes, including 22 protein coding genes and 7 lncRNAs (Sup Table 5). We found that some of the protein coding genes are reported to be associated with chemotherapy sensitivity. The over-expression of *TSPYL5* (testis-specific Y-encoded-like protein 5) and *TFAP2A* (transcription factor AP-2 alpha) are reported to increase the cell sensitivity to chemotherapy in different cancers^{20–23}. Moreover, in the Gray module, we also identified several lncRNAs that were consistently down-regulated in the docetaxel-resistant MCF7-RES and MDA-RES cells. Notably, an antisense lncRNA, EPB41L4A-AS2 (NONHSAG041250.2), which is reported to inhibit tumor proliferation and is associated with favorable prognoses in breast cancer²⁴, was identified as a hub gene in this module.

Location and functional analysis of the important lncRNAs and mRNAs in the resistance-associated modules. To uncover the relationship of the lncRNAs and the most studied MDR-related gene, *ABCB1*, we analyzed the genomic locations of the lncRNAs that were linked with *ABCB1* in the Turquoise module. Our results showed that several lncRNAs were localized at the regions overlapping or near the *ABCB1* gene locus. The locations of lncRNAs NONHSAG048134.2, NONHSAG048135.2 and NONHSAG096479.1 overlapped with *ABCB1*. NONHSAG048135.2 was transcribed in the same direction and was localized to the exons of the




Figure 4. Location and functional analysis of important lncRNAs closely linked to *ABCB1* mRNAs in the Turquoise module. **(A)** The location of *MRUL*, *ABCB1* and the four lncRNAs near the *ABCB1* locus. **(B)** Correlation between the expression of the 4 lncRNAs and the *ABCB1* gene. **(C)** The H3K4me1/H3K4me3 status at the TSS region (indicated by the red box) of the lncRNA NONHSAG048143.2. **(D)** The MRUL expression (FPKM) in the docetaxel-resistant cells (red bars) and parental cells (blue bars).

ABCB1 gene, indicating that it was an exonic lncRNA, whereas NONHSAG048134.2 and NONHSAG096479.1 were located in the antisense strand to the *ABCB1* gene locus, indicating that these two lncRNAs were antisense lncRNAs for the gene *ABCB1* (Fig. 4A). Another lncRNA, NONHSAG048143.2, was located 480 kb upstream of *ABCB1* (Fig. 4A).

The correlation analysis of the expression data of these four lncRNAs and *ABCB1* mRNA revealed a strong positive correlation between the expression of these lncRNAs and the *ABCB1* gene (Fig. 4B), suggesting that there was regulatory relationship between these lncRNAs and the *ABCB1* gene.

We downloaded the ChIP-seq (chromatin immunoprecipitation sequencing) datasets for MCF-7 and MDA-MB-231 breast cancer cells from the GEO (Gene expression omnibus) and ENCODE (encyclopedia of DNA elements) databases. By calculating the H3K4me1/H3K4me3 ratios at each TSS (transcriptional start site) of the lncRNAs near *ABCB1*, we found that the lncRNA NONHSAG048143.2, upstream of *ABCB1*, was associated with an enhancer-like chromatin state (H3K4me1/H3K4me3 ratio > 1.2) in both the MCF-7 and MDA-MB-231 cells (Fig. 4C). This indicated that NONHSAG048143.2 might function as an eRNA (enhancer lncRNA)²⁵ in the regulation of the *ABCB1* gene.

We also identified a previously reported lncRNA, NR_024549 (termed MRUL)¹⁰, which located 400 kb downstream of *ABCB1*. This lncRNA was found to be down-regulated in MCF7-RES cells (Fig. 4D).

The other lncRNA, EPB41L4A-AS2, which had been reported to be a potential tumor suppressor and prognostic biomarker was located head to head with the *EPB41L4A* gene in the antisense orientation (Fig. 5A). The correlation analysis on the expression data of this lncRNA and EPB41L4A and *ABCB1* mRNAs revealed strong positive correlation between the expression of EPB41L4A-AS2 and EPB41L4A (Pearson correlation test,




Figure 5. Location and functional analysis of the lncRNA EPB41L4A-AS2. (A) The location of the EPB41L4A-AS2 and EPB41L4A genes. (B) Correlation between the expression of EPB41L4A-AS2 and EPB41L4A and ABCB1. (C) The expression of EPB41L4A-AS2 (FPKM) in the docetaxel-resistant cells (red bars) and parental cells (blue bars). (D) The expression of EPB41L4A-AS2 in clinical breast cancers tissues (GSE21997) before neoadjuvant chemotherapy (doxorubicin and docetaxel).

$R = 0.892$, $P = 9.61 \times 10^{-5}$, Fig. 5B) but strong negative correlation between the expression of EPB41L4A-AS2 and ABCB1 genes (Pearson correlation test, $R = 0.774$, $P = 0.003$, Fig. 5B).

To validate the relationship between EPB41L4A-AS2 expression and chemotherapy resistance, we downloaded the primary microarray data GSE21997, which profile the RNA expression in primary breast cancers before neoadjuvant chemotherapy (doxorubicin and docetaxel)²⁶, from the GEO repository database. And the residual breast cancer burden (RCB) index was adopted to classified the breast cancer patients as previous report²⁷. Patients of RCB-III class were considered to be therapeutic resistant. By analyzing the microarray data, we found that the expression of EPB41L4A-AS2 was significantly lower (Student's t-test, $P = 0.042$, Fig. 5D) in the resistant group than the non-resistant group.

Real-time qPCR validation of important SDE lncRNAs and mRNAs. The qPCR results showed that the expression of the mRNAs, including ABCB1, ABCB4, ADAM22, COL21A1, GPNMB, and ITGB4 and the expressions of the lncRNAs, including NONHSAG096479.1, NONHSAG048134.2, NONHSAG048135.2, and




Figure 6. Real-time qPCR validation of important SDE lncRNAs and mRNAs. Validation of the important SDE lncRNAs and mRNAs in the MCF cells (**A**) and MDA cells (**B**). The heights of the red columns represent the logarithmically transformed mean fold-changes between the resistant and parental cells detected by QPCR. Data from three duplications are presented as mean \pm standard error. The blue columns represent the logarithmically transformed fold-changes between the resistant and parental groups detected by RNA-seq. 'Max' represents an infinitely large number due to the absence of NONHSAG096479.1 in the parental cells.

NONHSAG048143.2 were up-regulated in docetaxel resistant MCF7-RES and MDA-RES cell lines compared to their parental cells lines. On the contrary, the expressions of the mRNAs EPB41L4A and TSPYL5 and the expressions of the lncRNAs EPB41L4A-AS2 were down-regulated in docetaxel resistant MCF7-RES and MDA-RES cell lines compared to their parental cells lines (Fig. 6). The deregulated genes were identically regulated in both the MCF (Fig. 6A) and MDA (Fig. 6B) groups. Importantly, the qPCR analyses validated the results obtained by RNA-seq data.

Discussion

Taxanes are a class of anti-microtubule agents that have been demonstrated to be more efficient than anthracycline-based regimens and are listed as the first-line regimens for breast cancer^{28,29}. However, patients receiving taxane treatment usually develop resistance to taxanes, thus resulting in recurrence and metastasis³⁰.

To uncover the mechanisms underlying taxane resistance and find novel potential predictive biomarkers for clinical use, many studies have been carried out in both clinical cancer samples and resistant cell model systems^{4,31–38}. Through this research, a number of genes were identified to be associated with taxane resistance, and the differential expression of the *ABCB1* gene was extensively investigated and identified as one of the most credible biomarkers in chemotherapy-resistant cancers^{3,4,33,34,36,37}. However, these previous studies were mainly based on microarray hybridization technologies, and therefore, limited concordant differentially expressed genes are shared between the different studies^{3,4,33,34,36,37}, and the common denominator associated with taxane resistance remains largely unknown. Moreover, the underlying mechanism of taxane resistance in breast cancer and the regulators of taxane-resistant genes still needs to be uncovered.

lncRNAs regulate gene expression at the transcriptional and epigenetic levels³⁹. Recent studies have shown that lncRNAs are also implicated in tumor chemotherapy resistance^{9–13}. However, the contribution of lncRNAs to docetaxel resistance in breast cancer is still unclear.

Here, we used RNA-Seq technology (Illumina platform), which does not rely on pre-designed complement probes and shows a higher sensitivity in the detection of genes with very low expression and a higher accuracy in the detection of extremely abundant genes compared with microarray technology⁴⁰, to gain a more comprehensive and global profile of mRNAs and lncRNAs in docetaxel-resistant breast cancer cells (MCF7-RES and MDA-RES).

We detected an average of 26,329 lncRNAs and 13,010 mRNAs per sample. Importantly, the lncRNAs and mRNAs showed a high consistency between different passages from the same cell subline (Sup Figs 1A, 4A), which was in concordance with the reports on the high reproducibility of Illumina RNA-Seq⁴⁰ and demonstrated the reliability of these data.

We identified 1630 and 957 SDE coding genes in the MDA-RES and MCF7-RES groups compared to their parental cells, respectively. In comparison to the previous microarray analysis research in the same cell lines⁴, we identified more consistently up-regulated or down-regulated genes shared by the MCF7-RES and MDA-RES cells (124 vs 16), which are the potential common denominators associated with taxane resistance. The KEGG pathway analyses were performed on the SDE genes in each cell line, which identified the common pathways shared by the two cell lines and found that the most enriched pathways were different between the two cell lines (Sup Figs 2, 3). The 124 consistent SDE genes were also significantly enriched in 14 signaling pathways (Q-value < 0.05). The most significantly enriched pathway was the cGMP-PKG signaling pathway. However, the ABC transporters, the PI3K-Akt signaling pathway, and the AGE-RAGE signaling pathway in diabetic complications signaling pathway were also significantly enriched. Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiological processes. The role of this pathway in chemotherapy is unclear. However, it is implicated in the regulation of apoptosis in cancer cells⁴¹ and has been reported to mediate the inhibition of Pgp efflux function by YC-1⁴². The PI3K-Akt signaling pathway was the most significantly enriched pathway in the MDA-MB-231 cells (Sup Fig. 3) and was also significantly enriched in the MCF-7 cells. Although it has not been reported in the previous taxane-resistance studies in breast cancer^{3,4,33,34,36,37}, we found that it was linked to docetaxel resistance in prostate cancer^{43,44}. These results indicated that in addition to the classical pathways, such as the ABC transporters and ECM-receptor interaction pathways, other signaling pathways may also play important roles in taxane resistance in breast cancer.

In addition to the mRNA analysis, the more novel and important work here was the profiling of the lncRNAs in the parental and docetaxel-resistant breast cancer cells. We identified 72 consistently SDE lncRNAs (50 up-regulated and 22 down-regulated) in both of the docetaxel-resistant MCF-7 and MDA-MB-231 cell lines. By performing complete-linkage clustering with these consistently SDE lncRNAs, the 12 samples (3 samples for each of the 4 cell lines) perfectly clustered into two groups: the parental and resistant groups (Fig. 2D). A comparison of the clustering results with a similar number of SDE mRNAs (Fig. 1C) suggested that lncRNAs might be more specific biomarkers for distinguishing docetaxel-resistant cells from the non-resistant cells than mRNAs. Furthermore, this highlighted the potential application of lncRNAs as predictive biomarkers and for the prediction of response to chemotherapy.

lncRNAs have been described to exert their biological functions by regulating the generation and expression of target mRNAs⁸. Co-expression network analyses have been widely used to predict the target mRNAs of lncRNAs by detecting their similar expression patterns^{15,16}, and thus, the WGCNA R software package was used in our study to decipher the relationship between the SDE mRNAs and the SDE lncRNAs. By using a hierarchical clustering method, we identified 4 groups of co-expressed lncRNAs and mRNAs, termed 'modules'. Among these, the modules "Turquoise" and "Gray" were most significantly associated with a docetaxel-resistant status.

In the Turquoise module, which was positively correlated with docetaxel resistance, *ABCB1* was identified as one of the central and highly connected genes. We found that 39 genes, including 22 coding and 17 non-coding, were linked to *ABCB1* in this module. In the 22 coding genes linked to *ABCB1*, we found that many of the genes were implicated in drug or chemotherapy resistance. For instance, *ABCB4*, another ATP-binding cassette gene, which was reported to be involved in taxane resistance⁷, also clustered in this module. *ADAM22* was also closely linked to *ABCB1*. This gene has been reported to function as an estrogen receptor-independent mediator of endocrine-resistant breast cancer⁴⁵. However, it has not previously been linked to docetaxel resistance. Similarly, the gene *GPNMB* was also linked to *ABCB1* in the Turquoise module and was up-regulated in all the docetaxel-resistant cells. *GPNMB* has been shown to induce aggressive cellular phenotypes in breast cancer and has been identified as a potential therapeutic target for patients with basal-like breast cancer (BLBC) and TNBC^{46,47}. The concordant expression of *ABCB1* and other potential drug-resistant genes in docetaxel-resistant breast cancer cells indicates that besides *ABCB1*, there are also other genes that may play an important role in the generation of docetaxel resistance, and these genes may contribute to docetaxel resistance in a cooperative way with *ABCB1*. Pathway enrichment with the genes in this module highlighted the important roles of the PI3K-Akt and ABC transporter signaling pathways.

Moreover, a striking finding here is that many lncRNAs were also co-expressed with *ABCB1* and other potential drug-resistant genes in this module. We identified a list of lncRNAs closely linked to *ABCB1* in the Turquoise module (Table 2), indicating that some of these lncRNAs may function as regulators of *ABCB1*. By analyzing the genomic location of the lncRNAs linked with *ABCB1*, we found that several lncRNAs were located at the regions overlapping or near the *ABCB1* gene locus. The lncRNA NONHSAG048135.2 was identified as an exonic lncRNA of *ABCB1*, whereas NONHSAG048134.2 (termed *ABCB1-AS1*) and NONHSAG096479.1 (termed *ABCB1-AS2*) were identified as antisense lncRNAs for *ABCB1*. Another lncRNA, NONHSAG048143.2, was identified as an intergenic lncRNA located 480 kb upstream of *ABCB1*.

lncRNAs are implicated in a wide-spectrum of biological processes at different molecular levels, including epigenetic modifications, transcription, and post-transcriptional processing⁴⁸, and the functions of lncRNAs appears to always to be associated with the location of the lncRNA and the nearby mRNA^{49,50}. Antisense lncRNAs have been shown to bind to the complementary pre-mRNAs, regulate RNA editing and splicing and, finally, affect the expression levels of mRNAs and proteins^{51,52}. For instance, lncRNA ZEB2 NAT (zinc finger e-box binding homeobox 2 natural antisense transcript) was reported to bind to the ZEB2 pre-mRNA and obstruct the splicing of the Zeb2 5'-UTR, thus up-regulating the expression of the Zeb2 protein⁵². Antisense lncRNAs have also been shown to increase the stability of mRNAs by forming a lncRNA-mRNA duplex and, thereby, up-regulate gene expression^{53,54}. Although, the exact functions of the two novel antisense lncRNAs *ABCB1-AS1* and *ABCB1-AS2* are still unclear, and further research needs to be performed, our correlation analysis revealed a strong positive correlation between the expressions of these antisense lncRNAs and *ABCB1* mRNA (Fig. 4B) and raised the possibility that these lncRNAs may up-regulate the expression of the *ABCB1* gene via RNA splicing or stabilization mechanisms.

In addition to the lncRNAs located within the locus of the mRNAs, accumulating evidence suggests that lncRNAs located in the regulatory regions are also critical to the regulation of gene expression^{39,55}. Many lncRNA transcripts from enhancer regions have been shown to facilitate the transcription of protein-coding genes⁵⁶. For instance, CCAT1-L, which is transcribed from a super-enhancer region 500 kb upstream of the *MYC* (Proto-Oncogene C-Myc) gene, promotes chromatin interactions between *MYC* and its upstream regulatory elements and, thereby, up-regulates *MYC* transcription⁵⁷. Recently, a study of lncRNAs in doxorubicin- and vincristine-resistant gastric cancer cells also identified an lncRNA, MRUL, which is located 400 kb downstream of *ABCB1* and promotes the expression of *ABCB1*¹⁰. To our knowledge, this is the only lncRNA reported to promote *ABCB1* expression in chemotherapy-resistant cancer cells. Since this lncRNA has not been recorded in the NONCODE 2016 database, we analyzed the differential expression of the transcripts of MRUL between the parental MCF-7 and MDA-MB-231 cells and their docetaxel-resistant sublines. We found that MRUL was dramatically up-regulated in the docetaxel-resistant MCF-7 subline compared to the parental MCF-7 cells. However, this up-regulation was not apparent in the docetaxel-resistant MDA-MB-231 subline (Fig. 4D). This finding suggested that MRUL may also contribute to docetaxel resistance in ER (estrogen receptor) positive breast cancer but maybe not in the TNBC type.

Most intriguingly, in our study, we also identified the lncRNA NONHSAG048143.2 located 480 kb upstream of *ABCB1*. The correlation analysis revealed a strong positive correlation between the expression of this lncRNA and *ABCB1* mRNA (Fig. 4B), suggesting that this lncRNA may be another enhancer lncRNA for *ABCB1*. The histone H3K4me1/H3K4me3 ratio has been used to characterize enhancer elements across the genome^{25,58,59}. Therefore, we downloaded the ChIP-seq datasets of the MCF-7 and MDA-MB-231 breast cancer cells to calculate the H3K4me1/H3K4me3 ratios at the TSS of the lncRNA NONHSAG048143.2. Our result revealed that lncRNA NONHSAG048143.2 was located in a region presenting an enhancer-like chromatin state (H3K4me1/H3K4me3 ratio > 1.2) in both the MCF-7 and MDA-MB-231 cells (Fig. 4C). This result strongly suggested that this lncRNA might function as an enhancer lncRNA in the up-regulation of the *ABCB1* gene in docetaxel-resistant breast cancer cells.

In the Gray module, which was negatively correlated with the docetaxel-resistant status, we found that the gene *TSPYL5* was dramatically and consistently down-regulated in the docetaxel-resistant MCF-7 and MDA-MB-231 cells. This gene has been involved in the modulation of cell growth and the cellular response to gamma radiation probably via the regulation of the Akt signaling pathway⁶⁰. The overexpression of *TSPYL5* has also been linked to chemotherapy sensitivity in both lung and prostate cancer cells^{20,61}. The dramatic down-regulation of *TSPYL5* in the docetaxel-resistant breast cancer cells may be involved in the loss of docetaxel sensitivity. Interestingly, we found that the lncRNA EPB41L4A-AS2 was expressed in all the parental breast cancer cell lines but was absent in all the docetaxel-resistant descendants (Fig. 5C). According to a recent study, this lncRNA may inhibit tumor cell proliferation and is associated with favorable prognoses in breast cancer²⁴. However, the role of EPB41L4A-AS2 in chemotherapy-resistant cancer has not been deciphered yet. Here, we report, for the first time, the depletion of EPB41L4A-AS2 in docetaxel-resistant breast cancer cells. Our correlation analysis also showed that the decreased level of EPB41L4A-AS2 in the docetaxel-resistant breast cancer cells was significantly associated with an increased level of *ABCB1* mRNA (Fig. 5B). These results strongly indicate that the depletion of EPB41L4A-AS2 contributes to the docetaxel-resistant phenotype in breast cancer cells. In support of this notion, our analysis in clinical breast cancers tissues (GSE21997) before neoadjuvant chemotherapy (doxorubicin or docetaxel) also showed that the expression of EPB41L4A-AS2 was significantly lower in the patients resistant to neo-adjuvant chemotherapy than in non-resistant patients (Fig. 5D).

In conclusion, we performed a comprehensive Illumina-based RNA sequencing and analysis on two docetaxel-resistant breast cancer cell lines and their parental breast cancer cell lines. In addition to the most studied docetaxel-resistant gene, *ABCB1*, we also identified other SDE protein-coding genes and pathways, which might contribute to the generation of docetaxel resistance. These findings improved our understanding of the mechanism underlying docetaxel resistance in breast cancer and suggest that a number of lncRNAs are promising candidates as predictive biomarkers for the docetaxel response. To our knowledge, this is the first study to report on a global profile of mRNAs and lncRNAs in docetaxel-resistant breast cancer. We identified groups of lncRNAs, which were consistently up-regulated or down-regulated in both the docetaxel-resistant MCF-7 and MDA-MB-231 cell lines and constructed a co-expression network to decipher the potential regulatory relationship between the SDE lncRNAs and mRNAs. Our results highlighted four overexpressed lncRNAs that overlapped or were near the *ABCB1* locus, which might up-regulate the expression of *ABCB1* via different mechanisms. We also identified lncRNA EPB41L4A-AS2 as a potential biomarker for docetaxel sensitivity in clinical breast cancer samples. Although further basic biological and clinical research still needs to be performed to explore the exact biological function of these newly identified lncRNAs, our study provided potential biomarkers to predict the response to docetaxel in breast cancer patients and might help improve the strategy for the treatment of advanced breast cancer.

Methods

Cell culture and treatment. The two human breast cancer cell lines MDA-MB-231 and MCF-7 and their docetaxel-resistant sublines MDA-RES and MCF7-RES were obtained from Hansen *et al.*'s study⁴.

The MCF-7 cells were cultured in DMEM (Gibco, Thermo Fisher Scientific, USA) plus 1% non-essential amino acids (Gibco, Thermo Fisher Scientific, USA) and 5% fetal calf serum (FCS) (Gibco, Thermo Fisher Scientific, USA). The MDA-MB-231 cells were cultured in DMEM plus 10% FCS. The culture medium for the MDA-RES and MCF7-RES cells was the same as their parental cells except for the supplementation of 65 or 150 nM of docetaxel (Sanofi Aventis, France), respectively. All the cell lines were grown in 5% carbon dioxide at 37 °C.

Total RNA purification and rRNA depletion transcriptome Sequencing. For the Illumina-based RNA-Seq, the total RNA from 3 passages of MCF-7, MCF7-RES, MDA-MB-231 and MDA-RES, was purified with RNAiso Plus Kit (TAKARA, Japan). After the RNA purification and DNase I digestion, rRNAs were removed from the total RNA with RiboMinus Eukaryote Kit (Qiagen, USA). The remained RNAs were fragmented using Ambion Fragmentation Solution (Thermo Fisher Scientific, USA). Then the mRNA fragments were used to synthesize cDNAs, followed by end repairing and adenine connection. Sequencing adaptors were ligated the fragments. Suitable fragments were selected according to the agarose gel electrophoresis results for PCR amplification. The StepOnePlus System (Applied Biosystems, Thermo Fisher Scientific, USA) and the Agilent 2100 Bioanalyzer (Agilent Technologies, USA) were used to quantify and qualify the sample libraries in the QC steps. Finally, all the libraries were sequenced by the HiSeq. 2000 sequencer (Illumina, USA).

lncRNA and mRNA expression profiling. Firstly, adaptor sequences were removed from the raw reads. And low quality reads, which contained more than 50% of low quality bases (base quality < 10) and 5% of undefined nucleotides [N] on the read, were also removed. To avoid the reads mapped to the remaining rRNAs disturbing the next analysis, we aligned the reads to the human ribosomal RNA sequences (rRNA) and filtered out the perfect mapping reads. After the above two-step filtering, the remaining reads were considered clean reads and were used in next expression profile. In the mRNA analysis, the clean reads were mapped to the human reference genome (hg19) by TopHat2⁶². Then, the genes annotated in RefSeq were quantified by Cufflinks tools⁶³. For lncRNA, the clean reads were mapped to the noncoding RNA transcriptome (NONCODE 2016⁶⁴) by STAR⁶⁵ and quantified by RSEM⁶⁶. The parameters used in the analysis tools referred to the ENCODE RNA-seq data processing pipelines (<https://www.encodeproject.org/pipelines/>). Finally, we obtained all the mRNA and lncRNA expression tables represented in both the FPKM and read-count format.

Identification of significantly differentially expressed lncRNAs and mRNAs. The differentially expressed lncRNAs and mRNAs between the parental and docetaxel-resistant cells groups were calculated by DESeq⁶⁷ in the two cell lines, respectively. To ensure that the denominator was not zero when performing the division operation, we added 1 to every element in the read-count matrix. The P-value was calculated based on a negative binomial distribution model, and adjusted by Benjamini-Hochberg method. The criteria of $|\text{Log2FC}| > 1$, $\text{FDR} < 0.1$ was used to select the significantly differentially expressed lncRNAs and mRNAs.

GO and KEGG pathway enrichment. Functional annotation enrichment analyses for GO and the KEGG pathway were performed using the KOBAS server⁶⁸. P-value is calculated by hypergeometric test. The Q-value is the P-value corrected by Benjamini-Hochberg method. The GO terms and pathways with a Q value less than 0.05 were considered significantly enriched.

Co-expression network analysis. The WGCNA R package¹⁸ was used to construct the co-expression network between the significantly differentially expressed lncRNAs and mRNAs.

By hierarchical clustering of the expression data, several modules, which are clusters of highly interconnected genes, were identified in the co-expression network. Then, we related the drug-resistant feature to the module eigengene to identify the drug-resistant modules (Pearson correlation test, $P\text{-value} < 0.05$). In the drug-resistant modules, hub genes were selected by $|\text{MM}| > 0.8$ and $|\text{GS}| > 0.4$, and they were highly connected with other genes. The connections among the hub genes were visualized as an unsigned network by Cytoscape⁶⁹.

Classification of lncRNAs near ABCB1 with the downloaded ChIP-seq (H3K4me1/H3K4me3) data. We downloaded the ChIP-seq datasets for the MCF-7 and MDA-MB-231 breast cancer cells from the GEO and ENCODE website. The NCBI (National Center for Biotechnology Information) accession number for the MDA-MB-231 cell ChIPseq data is GSE49651. The ENCODE accessions for the MCF-7 cell datasets are ENC493NBY and ENC498MIB. Then, we calculated the H3K4me1/H3K4me3 ratio at each TSS (mean over interval, 1 kb up and down TSS).

Validation of the SDE mRNAs and lncRNAs. The PCR primers for the eight selected mRNAs (including ABCB1, ABCB4, ADAM22, COL21A1, GPNMB, ITGB4, and EPB41L4A) and the five lncRNAs (including EPB41L4A-AS2, NONHSAG096479.1, NONHSAG048134.2, NONHSAG048135.2, and NONHSAG048143.2) were designed using Primer 5.0 (Sup Table 6). The PCR primers for GAPDH was also designed to serve as the endogenous control. The length of the PCR products ranged from 100 bp to 400 bp (Sup Table 6). Total RNAs from each cell line was extracted using RNAiso Plus (TAKARA, Japan), and examined Qubit fluorometer (Invitrogen, Thermo Fisher Scientific, USA). QPCR was performed in triplicate on an StepOnePlus instrument (Applied Biosystems, Thermo Fisher Scientific, USA) using the SYBR Premix Ex Taq II (TAKARA, Japan) reagent. ROX dye II was applied for baseline correction. The relative expressions of the mRNA and lncRNAs were calculated with the $2^{-\Delta\Delta\text{Ct}}$ method.

References

1. Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M. & Jemal, A. (AACR, 2017).
2. King, K. M. *et al.* Optimal use of taxanes in metastatic breast cancer. *Current oncology* **16**, 8–20 (2009).
3. Kim, H. J. *et al.* ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. *Cancer science* **106**, 86–93 (2015).
4. Hansen, S. N. *et al.* Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. *Tumor Biology* **36**, 4327–4338 (2015).
5. Chen, C.-j. *et al.* Internal duplication and homology with bacterial transport proteins in the *mdr1* (P-glycoprotein) gene from multidrug-resistant human cells. *Cell* **47**, 381–389 (1986).

6. Leonessa, F. & Clarke, R. ATP binding cassette transporters and drug resistance in breast cancer. *Endocrine-related cancer* **10**, 43–73 (2003).
7. Hansen, S. N. *et al.* The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. *BMC genomics* **17**, 442 (2016).
8. Geisler, S. & Coller, J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nature reviews Molecular cell biology* **14**, 699–712 (2013).
9. Liu, Z. *et al.* The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21 WAF1/CIP1 expression. *PloS one* **8**, e77293 (2013).
10. Wang, Y. *et al.* Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. *Molecular and cellular biology* **34**, 3182–3193 (2014).
11. Pan, Y. *et al.* Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. *Oncotarget* **8**, 33144 (2017).
12. Chen, J. *et al.* Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. *Oncotarget* **7**, 62474 (2016).
13. Jiang, Y. Z. *et al.* Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. *Cancer research* **76**, 2105–2114, <https://doi.org/10.1158/0008-5472.CAN-15-3284> (2016).
14. Batista, P. J. & Chang, H. Y. Long noncoding RNAs: cellular address codes in development and disease. *Cell* **152**, 1298–1307 (2013).
15. Liao, Q. *et al.* Large-scale prediction of long non-coding RNA functions in a coding–non-coding gene co-expression network. *Nucleic acids research* **39**, 3864–3878 (2011).
16. Zhang, T. *et al.* Analysis of long noncoding RNA and mRNA using RNA sequencing during the differentiation of intramuscular preadipocytes in chicken. *PloS one* **12**, e0172389 (2017).
17. Li, C. *et al.* Integrative analyses of transcriptome sequencing identify novel functional lncRNAs in esophageal squamous cell carcinoma. *Oncogenesis* **6**, e297 (2017).
18. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC bioinformatics* **9**, 559, <https://doi.org/10.1186/1471-2105-9-559> (2008).
19. de Jong, S. *et al.* A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. *PloS one* **7**, e39498 (2012).
20. Lakshmanan, I. *et al.* MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. *Clinical Cancer Research* (2017).
21. Nordentoft, I. *et al.* Increased expression of transcription factor TFAP2 α correlates with chemosensitivity in advanced bladder cancer. *BMC cancer* **11**, 135 (2011).
22. Jonckheere, N. *et al.* Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2 α overexpression. *British journal of cancer* **101**, 637–644 (2009).
23. Tan, E.-H. *et al.* A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. *Annals of oncology* **21**, 217–222 (2010).
24. Xu, S. *et al.* The long non-coding RNA EPB41L4A-AS2 inhibits tumor proliferation and is associated with favorable prognoses in breast cancer and other solid tumors. *Oncotarget* **7**, 20704 (2016).
25. Iliot, N. E. *et al.* Long non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-induced inflammatory response in human monocytes. *Nature communications* **5** (2014).
26. Romero, A. *et al.* Glutathione S-transferase P1 c. 313 A>G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. *Annals of oncology*, mdr483 (2011).
27. Symmans, W. F. *et al.* Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *Journal of Clinical Oncology* **25**, 4414–4422 (2007).
28. Nabholz, J.-M. *et al.* Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. *Journal of Clinical Oncology* **21**, 968–975 (2003).
29. Nabholz, J., Paterson, A. & Dirix, L. In *Proc Am Soc Clin Oncol*
30. Brooks, T. *et al.* Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. *Molecular cancer therapeutics* **2**, 1195–1205 (2003).
31. Chang, J. C. *et al.* Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. *The Lancet* **362**, 362–369 (2003).
32. Martin, M. *et al.* Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. *Breast cancer research and treatment* **128**, 127 (2011).
33. İşeri, Ö. D., Kars, M. D. & Gündüz, U. Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. *Molecular biology reports* **39**, 3505–3516 (2012).
34. Kars, M. D., İşeri, Ö. D. & Gündüz, U. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells. *European journal of pharmacology* **657**, 4–9 (2011).
35. İşeri, Ö. D., Kars, M. D., Arpacı, F. & Gündüz, U. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. *Cancer chemotherapy and pharmacology* **65**, 447–455 (2010).
36. Kars, M. D., İşeri, Ö. D. & Gündüz, U. Drug resistant breast cancer cells overexpress ETS1 gene. *Biomedicine & Pharmacotherapy* **64**, 458–462 (2010).
37. Villeneuve, D. J. *et al.* cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. *Breast cancer research and treatment* **96**, 17–39 (2006).
38. Duan, Z., Lamendola, D. E., Duan, Y., Yusuf, R. Z. & Seiden, M. V. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. *Cancer chemotherapy and pharmacology* **55**, 277–285 (2005).
39. Xiong, X.-d. *et al.* Long non-coding RNAs: An emerging powerhouse in the battle between life and death of tumor cells. *Drug Resistance Updates* **26**, 28–42 (2016).
40. Zhao, S., Fung-Leung, W.-P., Bittner, A., Ngo, K. & Liu, X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. *PloS one* **9**, e78644 (2014).
41. Ren, Y., Zheng, J., Yao, X., Weng, G. & Wu, L. Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells. *International journal of molecular medicine* **34**, 1430–1438 (2014).
42. Hung, C.-C. & Liou, H.-H. YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. *Investigational new drugs* **29**, 1337–1346 (2011).
43. Chen, H., Li, H. & Chen, Q. INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer. *Biochemical and Biophysical Research Communications* **477**, 467–472 (2016).
44. Liu, Z., Zhu, G., Getzenberg, R. H. & Veltri, R. W. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. *Journal of cellular biochemistry* **116**, 1341–1349 (2015).
45. McCartan, D. *et al.* Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. *Cancer research* **72**, 220–229 (2012).
46. Maric, G., Rose, A., Annis, M. G. & Siegel, P. M. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. *Onco Targets Ther* **6**, 839–852 (2013).
47. Yardley, D. *et al.* (AACR, 2012).

48. Li, X., Wu, Z., Fu, X. & Han, W. Long noncoding RNAs: insights from biological features and functions to diseases. *Medicinal research reviews* **33**, 517–553 (2013).
49. Mercer, T. R. & Mattick, J. S. Structure and function of long noncoding RNAs in epigenetic regulation. *Nature structural & molecular biology* **20**, 300–307 (2013).
50. Guttman, M. *et al.* Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* **458**, 223–227 (2009).
51. Salameh, A. *et al.* PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. *Proceedings of the National Academy of Sciences* **112**, 8403–8408 (2015).
52. Beltran, M. *et al.* A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial–mesenchymal transition. *Genes & development* **22**, 756–769 (2008).
53. Huang, B. *et al.* Long non-coding antisense RNA KRT7-AS is activated in gastric cancers and supports cancer cell progression by increasing KRT7 expression. *Oncogene* **35**, 4927–4936 (2016).
54. Faghihi, M. A. *et al.* Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β -secretase. *Nature medicine* **14**, 723–730 (2008).
55. Engreitz, J. M. *et al.* Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* **539**, 452–455 (2016).
56. Natoli, G. & Andrau, J.-C. Noncoding transcription at enhancers: general principles and functional models. *Annual review of genetics* **46**, 1–19 (2012).
57. Xiang, J.-F. *et al.* Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. *Cell research* **24**, 513–531 (2014).
58. De Santa, F. *et al.* A large fraction of extragenic RNA pol II transcription sites overlap enhancers. *PLoS Biol* **8**, e1000384 (2010).
59. Marques, A. C. *et al.* Chromatin signatures at transcriptional start sites separate two equally populated yet distinct classes of intergenic long noncoding RNAs. *Genome biology* **14**, R131 (2013).
60. Kim, E. J. *et al.* TSPYL5 is involved in cell growth and the resistance to radiation in A549 cells via the regulation of p21 WAF1/Cip1 and PTEN/AKT pathway. *Biochemical and biophysical research communications* **392**, 448–453 (2010).
61. Kumar, S. R., Bryan, J. N., Esebua, M., Amos-Landgraf, J. & May, T. J. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma. *BMC cancer* **17**, 158 (2017).
62. Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome biology* **14**, R36 (2013).
63. Trapnell, C. *et al.* Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nature biotechnology* **28**, 511–515 (2010).
64. Zhao, Y. *et al.* NONCODE 2016: an informative and valuable data source of long non-coding RNAs. *Nucleic acids research* **44**, D203–D208 (2016).
65. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
66. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC bioinformatics* **12**, 323 (2011).
67. Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome biology* **11**, R106 (2010).
68. Wu, J., Mao, X., Cai, T., Luo, J. & Wei, L. KOBAS server: a web-based platform for automated annotation and pathway identification. *Nucleic acids research* **34**, W720–W724 (2006).
69. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome research* **13**, 2498–2504 (2003).

Acknowledgements

This work was funded by the National Natural Science Foundation of China (81502412), the Scientific Research Projects of Shenzhen Health System (201501015), and the Guangzhou science and technology program key projects (201604020005). The authors would like to thank the contributors of the microarray dataset GSE21997 and the ChIP-seq datasets of GSE49651, ENCSR493NBY and ENCSR985MIB.

Author Contributions

N.B., P.H. and J.S. conceived the study and analyses. Y.Y., S.L., and Z.D. performed the sequencing. P.H., F.L. and L.L. performed the bioinformatics analysis. P.H. wrote the manuscript. J.S., N.B. and S.W. revised the manuscript. N.B., S.W. and Q.G. supervised and supported this project.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-018-36231-4>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018